REYKJAVIK, Iceland, Feb. 6 /PRNewswire-FirstCall/ -. deCODE genetics today announced that its presentation at Nasdaq's U.S. Small Cap Conference will be webcast live. deCODE CEO Dr. Kari Stefansson will provide an overview of the company's drug development programs and business.
The presentation will be delivered at 10am GMT/5am EST on Wednesday, February 8, 2006, at the Merrill Lynch Financial Centre in London. The webcast can be accessed through the Investors page on deCODE's website, http://www.decode.com, or through the Nasdaq website at http://investors.nasdaq.com. The webcast will be archived for at least one week on both sites. Those interested in listening should log on a few minutes in advance, in order to download any software or complete any sign-in that may be required.
About deCODE
deCODE genetics is a biopharmaceutical company applying its discoveries in human genetics to the development of drugs for common diseases. deCODE is a global leader in gene discovery -- our population approach and resources have enabled us to isolate key genes contributing to major public health challenges from cardiovascular disease to cancer, genes that are providing us with drug targets rooted in the basic biology of disease. deCODE is also leveraging its expertise in human genetics and integrated drug discovery and development capabilities to offer innovative products and services in DNA-based diagnostics, bioinformatics, genotyping, structural biology, drug discovery and clinical development. deCODE is delivering on the promise of the new genetics(SM). Visit us on the web at http://www.decode.com.
Contact: deCODE genetics Stefan Arnason +354 570 1995 ir@decode.is
deCODE geneticsCONTACT: Stefan Arnason of deCODE genetics, +1-354-570-1995, ir@decode.is
